Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | CRISPR-Cas9 genome editing technology in the development of T cell therapies

Alessio Nahmad • 31 Mar 2022
ICLE 2022
General

Alessio Nahmad, PhD, Tel Aviv University, Tel Aviv, Israel, explains how genome editing technology can be utilized in the development of T cell-based therapies. Selective gene ablation using CRISPR-Cas9 technology can help enhance efficiency, reduce toxicity and reduce cellular exhaustion in T cell products such as chimeric antigen receptor (CAR)-T cell and T cell receptor (TCR) therapies. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Related Videos

2:30
The impact of conflict on access to cancer therapies
Richard Sullivan • 29 Apr 2024
3:11
Exercise as an underutilized tool in cancer care
Rebecca Robinson • 23 Apr 2024
2:15
Cardiac biomarkers for immune checkpoint inhibitor-related myocarditis in cancer patients
Arjun Ghosh • 25 Apr 2024
1:09
Rethinking healthcare to improve affordability, sustainability, and patient outcomes
Richard Sullivan • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals